The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone ...

MEDSIR, a leading company dedicated to promoting independent clinical research in oncology internationally and part of ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma.

The drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...